Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Quick facts
Phase 3 pipeline
- TR-701 FA · Infectious Disease
TR-701 FA is a prodrug of TR-700 that inhibits bacterial protein synthesis by binding to the bacterial ribosome.
Phase 2 pipeline
Phase 1 pipeline
- Human ADME
- TR-701
- TR-701 di-sodium phosphate salt
- TR-701 FA single infusion
- TR-701 FA tablets
- TR-701 FA with PSE
- TR-701 FA with Tyramine
- TR-701 free acid phosphate
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) portfolio CI brief
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) pipeline updates RSS
Frequently asked questions about Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
What is Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)'s pipeline?
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) has 1 drugs in Phase 3, 1 in Phase 2, 8 in Phase 1. Late-stage candidates include TR-701 FA.
Related
- Sector hub: All tracked pharma companies